Cargando…

Health Plan Budget Impact Analysis for Pimecrolimus

OBJECTIVES: Budget impact models are useful tools for managed care organizations to make drug formulary decisions. The objective of this study was to estimate the incremental budgetary change in per-member-per-month (PMPM) medical and pharmacy costs for atopic dermatitis (AD) or eczema after the int...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Jane, Sung, Jennifer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2005
Materias:	Formulary Management
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437532/ https://www.ncbi.nlm.nih.gov/pubmed/15667234 http://dx.doi.org/10.18553/jmcp.2005.11.1.66

Ejemplares similares

Administrative Claims Analysis of Utilization and Costs of Care in Health Plan Members With Atopic Dermatitis Who Had Prior Use of a Topical Corticosteroid and Who Initiate Therapy With Pimecrolimus or Tacrolimus
por: Delea, Thomas E., et al.
Publicado: (2007)

Formulary Review of Therapeutic Alternatives for Atopic Dermatitis: Focus on Pimecrolimus
por: Weinberg, Jeffery M.
Publicado: (2005)

Evaluation of Erlotinib in Advanced Non-Small Cell Lung Cancer: Impact on the Budget of a U.S. Health Insurance Plan
por: Ramsey, Scott D., et al.
Publicado: (2006)

Pharmacy Benefit Forecast for a New Interferon Beta-1a for the Treatment of Multiple Sclerosis: Development of a First-Line Decision Tool for Pharmacy-Budget Planning Using Administrative Claims Data
por: Meryer, Christina
Publicado: (2003)

Evaluation of Omalizumab From a Health Plan Perspective
por: Belliveau, Paul P., et al.
Publicado: (2005)

AMCP Format Dossier Requests: Manufacturer Response and Formulary Implications for One Large Health Plan
por: Spooner, Joshua J., et al.
Publicado: (2007)

Clinical and Economic Outcomes of Conversion of Simvastatin to Lovastatin in a Group-Model Health Maintenance Organization
por: Billups, Sarah J., et al.
Publicado: (2005)

Cost-EffectivenessAnalysis of Ondansetron and Prochlorperazine for the Prevention of Postoperative Nausea andVomiting
por: Chang, Peter
Publicado: (2005)

Examining the Value and Quality of Health Economic Analyses: Implications of Utilizing the QHES
por: Ofman, Joshua J., et al.
Publicado: (2003)

Cost-effectiveness of Four Immunomodulatory Therapies for Relapsing-Remitting Multiple Sclerosis: A Markov Model Based on Long-term Clinical Data
por: Bell, Christopher, et al.
Publicado: (2007)

Multicenter Drug Use Evaluation of Tamsulosin and Availability of Guidance Criteria for Nonformulary Use in the Veterans Affairs Health System
por: Burk, Muriel, et al.
Publicado: (2004)

Cost-Effectiveness Analysis and the Formulary Decision-Making Process
por: Wang, Zhixiao, et al.
Publicado: (2004)

A Population Approach to Disease Management: Hepatitis C Direct-Acting Antiviral Use in a Large Health Care System
por: Belperio, Pamela S., et al.
Publicado: (2014)

Cost and Utilization Comparisons Among Propensity Score-Matched Insulin Lispro and Regular Insulin Users
por: Hall, Jennifer A., et al.
Publicado: (2003)

Observational Study of the Prevalence of Febrile Neutropenia in Patients Who Received Filgrastim or Pegfilgrastim Associated With 3-4 Week Chemotherapy Regimens in Community Oncology Practices
por: Morrison, Vicki A., et al.
Publicado: (2007)

Cost-Minimization Analysis of Once-Weekly Versus Thrice-Weekly Epoetin Alfa for Chemotherapy-Related Anemia
por: Cremieux, Pierre Y., et al.
Publicado: (2004)

Cost-Effectiveness Analysis of Simvastatin and Lovastatin/Extended-Release Niacin to Achieve LDL and HDL Goal Using NHANES Data
por: Armstrong, Edward P., et al.
Publicado: (2004)

Cost-Efficacy Analysis of Peginterferon alfa-2b plus Ribavirin Compared With Peginterferon alfa-2a plus Ribavirin for the Treatment of Chronic Hepatitis C
por: Malone, Daniel C., et al.
Publicado: (2005)

Clinical Monograph for Drug Formulary Review: Systemic Agents for Psoriasis/Psoriatic Arthritis
por: Fisher, Vicki S.
Publicado: (2005)

Similar Medication Compliance and Control of Dyslipidemia WithSimvastatin or Atorvastatin in a Staff-Model HMO Medical Clinic
por: Valdez, Connie A., et al.
Publicado: (2005)

Triptans for Migraine Therapy: A Comparison Based on Number Needed to Treat and Doses Needed to Treat
por: Mullins, C. Daniel
Publicado: (2005)

Clinical Monograph for Drug Formulary Review: Erectile Dysfunction Agents
por: Campbell, Helen Eloise
Publicado: (2005)

Product-Line Extensions and Pricing Strategies of Brand-Name Drugs Facing Patent Expiration
por: Hong, Song Hee, et al.
Publicado: (2005)

Effect of Patient Notification of Formulary Change on Formulary Adherence
por: Delate, Thomas, et al.
Publicado: (2005)

A Comparison of Clinical Practice Guidelines in the Initial Pharmacological Management of New-Onset Epilepsy in Adults
por: Payakachat, Nalin, et al.
Publicado: (2006)

The U.S. Food and Drug Administration: Drug Information Resource for Formulary Recommendations
por: Marchand, Heidi C., et al.
Publicado: (2012)

Critical Review of Prasugrel for Formulary Decision Makers
por: Schafer, Jeremy
Publicado: (2009)

Proton-Pump Inhibitor Utilization Associated With the Change to Nonpreferred Formulary Status for Esomeprazole in the TRICARE Formulary
por: Linton, Andrea, et al.
Publicado: (2009)

Application of Economic Analyses in U.S. Managed Care Formulary Decisions: A Private Payer's Experience
por: Watkins, John B., et al.
Publicado: (2006)

Cost-Effectiveness of Tamsulosin, Doxazosin, and Terazosin in the Treatment of Benign Prostatic Hyperplasia
por: Ohsfeldt, Robert L., et al.
Publicado: (2004)

Formulary Management of the Protease Inhibitors Boceprevir and Telaprevir for Chronic Hepatitis C Virus
por: Tungol, Alexandra, et al.
Publicado: (2011)

Formulary Management of 2 New Agents: Lorcaserin and Phentermine/Topiramate for Weight Loss
por: Kelly, Elizabeth M., et al.
Publicado: (2013)

Comparison of Risedronate to Alendronate and Calcitonin for Early Reduction of Nonvertebral Fracture Risk: Results From a Managed Care Administrative Claims Database
por: Watts, Nelson B., et al.
Publicado: (2004)

Assessment of Clinical, Service, and Cost Outcomes of a Conversion Program of Sumatriptan to Rizatriptan ODT in Primary Care Patients With Migraine Headaches
por: Gershovich, Olga E., et al.
Publicado: (2006)

Drug and Medical Cost Effects of a Drug Formulary Change With Therapeutic Interchange for Statin Drugs in a Multistate Managed Medicaid Organization
por: Meissner, Brian, et al.
Publicado: (2006)

Managed Care Perspective on Three New Agents for Type 2 Diabetes
por: VanDeKoppel, Shawna, et al.
Publicado: (2008)

Industry's Perception of Presenting Pharmacoeconomic Models to Managed Care Organizations
por: Olson, Bridget M., et al.
Publicado: (2003)

Determinants of the Cost-Effectiveness of Statins
por: Morrison, Alan, et al.
Publicado: (2003)

Do Decision-Analytic Models Identify Cost-Effective Treatments? A Retrospective Look at Helicobacter Pylori Eradication
por: Fairman, Kathleen A., et al.
Publicado: (2003)

Alternate Financial Incentives in Multi-tiered Formulary Systems to Improve Accountability for Outcomes
por: Chung, Richard S., et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_2l9dqeivtiohosgb3p2ujo2d2o